glp-1 ras drugs 🔸 Should be continued preprocedurally? 🔸 Who should stop a GLP-1 RA preoperatively? 🔸 Which patients should have their procedures postponed? “Perioperative Management of Patients Taking GLP-1 Receptor Agonists” explores GLP-1 medicines started with injectable

It will depend on the individuals needs

All in one to reach your goals

REIMAGINE 2 was a 68-week efficacy and safety phase 3 trial of CagriSema 2.4 mg/2.4 mg and 1 mg/1 mg once-weekly versus semaglutide 2.4 mg, semaglutide 1 mg, cagrilintide 2.4 mg, and placebo in 2,713 adults with type 2 diabetes inadequately controlled with metformin with or without an SGLT2 inhibitor

Obesity Disease Burden and Population Health ROI Framework Economic Cost of Obesity, Comorbidity Cascade, and GLP-1 Pharmacotherapy Value-Based Evidence Reshape Global Treatment Investment The Global Obesity Forum estimated total annual economic costs of obesity at USD 4.32 trillion annually in 2025 , representing 2.92% of global GDP and exceeding the full economic output of Germany